Novo Nordisk strikes potential $2B-plus gene editing deal with Durham’s Life Edit

Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Here are the details.

Read More